Literature DB >> 19814789

Seroprevalence of HBV and HCV in primary hepatocellular carcinoma patients in Zimbabwe.

Nyasha Chin'ombe1,2, Evans Chavhunduka2,3, Hilda T Matarira2,4.   

Abstract

BACKGROUND: Primary hepatocellular carcinoma (PHC) is one of the most common cancers in Zimbabwe. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are suspected to play a major role in causing this cancer. The objective of this study was to determine the seroprevalence of HBV and HCV in PHC at Parirenyatwa Referral Hospital in Zimbabwe. We evaluated the serological markers of the two viruses in patients with PHC using commercially available enzyme-linked immunosorbent kits.
RESULTS: Out of the 60 patients with PHC, 48.3% were seropositive for HBV and 20.0% were seropositive for HCV. Co-infection by HCV and HBV was found in 8% of the patients. Only 13.3% of the health controls (blood donors) were positive for HBV. All the controls were negative for HCV.
CONCLUSION: The high seropositivity of HBV and HCV in PHC in Zimbabwe suggested that the two viruses were a major cause of the cancer.

Entities:  

Year:  2009        PMID: 19814789      PMCID: PMC2764566          DOI: 10.1186/1750-9378-4-15

Source DB:  PubMed          Journal:  Infect Agent Cancer        ISSN: 1750-9378            Impact factor:   2.965


  30 in total

Review 1.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

2.  Chronic hepatitis B.

Authors:  Anna S F Lok
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

Review 3.  Part I: Cancer in Indigenous Africans--burden, distribution, and trends.

Authors:  D Max Parkin; Freddy Sitas; Mike Chirenje; Lara Stein; Raymond Abratt; Henry Wabinga
Journal:  Lancet Oncol       Date:  2008-07       Impact factor: 41.316

4.  Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993-1995.

Authors:  E Chokunonga; L M Levy; M T Bassett; B G Mauchaza; D B Thomas; D M Parkin
Journal:  Int J Cancer       Date:  2000-01-01       Impact factor: 7.396

5.  Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.

Authors:  Giovanna Fattovich; Maurizio Pantalena; Irene Zagni; Giuseppe Realdi; Solko W Schalm; Erik Christensen
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

Review 6.  Chronic hepatitis B virus infection: treatment strategies for the next millennium.

Authors:  A H Malik; W M Lee
Journal:  Ann Intern Med       Date:  2000-05-02       Impact factor: 25.391

Review 7.  HCV genotypes--role in pathogenesis of disease and response to therapy.

Authors:  G Webster; E Barnes; D Brown; G Dusheiko
Journal:  Baillieres Best Pract Res Clin Gastroenterol       Date:  2000-04

Review 8.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

9.  Hepatitis C virus in Zimbabwe.

Authors:  I T Gangaidzo; V M Moyo; H Khumalo; T Saungweme; Z Gomo; T Rouault; V R Gordeuk
Journal:  Cent Afr J Med       Date:  1997-05

10.  Hepatitis B virus infection.

Authors:  Yun-Fan Liaw; Chia-Ming Chu
Journal:  Lancet       Date:  2009-02-14       Impact factor: 79.321

View more
  3 in total

1.  Therapy and prognostic features of primary clear cell carcinoma of the liver.

Authors:  Sheng-Pu Ji; Qiang Li; Hui Dong
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

2.  Progress on the elimination of viral hepatitis in Zimbabwe: A review of the policies, strategies and challenges.

Authors:  Blessing Dzingirai; Leolin Katsidzira; Celia Moffat Joel Matyanga; Maarten Jacobus Postma; Marinus van Hulst; Nyashadzaishe Mafirakureva
Journal:  J Viral Hepat       Date:  2021-04-09       Impact factor: 3.728

3.  Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders.

Authors:  Donatien Serge Mbaga; Sebastien Kenmoe; Cyprien Kengne-Ndé; Jean Thierry Ebogo-Belobo; Gadji Mahamat; Joseph Rodrigue Foe-Essomba; Marie Amougou-Atsama; Serges Tchatchouang; Inès Nyebe; Alfloditte Flore Feudjio; Ginette Irma Kame-Ngasse; Jeannette Nina Magoudjou-Pekam; Lorraine K M Fokou; Dowbiss Meta-Djomsi; Martin Maïdadi-Foudi; Sabine Aimee Touangnou-Chamda; Audrey Gaelle Daha-Tchoffo; Abdel Aziz Selly-Ngaloumo; Rachel Audrey Nayang-Mundo; Jacqueline Félicité Yéngué; Jean Bosco Taya-Fokou; Raoul Kenfack-Momo; Efietngab Atembeh Noura; Cynthia Paola Demeni Emoh; Hervé Raoul Tazokong; Arnol Bowo-Ngandji; Carole Stéphanie Sake; Etienne Atenguena Okobalemba; Jacky Njiki Bikoi; Richard Njouom; Sara Honorine Riwom Essama
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.